CBHD:F:F-Coloplast A/S (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 126.5

Change

-0.15 (-0.12)%

Market Cap

USD 27.31B

Volume

30.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-2.05 (-0.47%)

USD 158.73B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-3.00 (-2.88%)

USD 95.76B
ESL:F EssilorLuxottica Société ano..

-0.30 (-0.15%)

USD 95.72B
BOX:F Becton Dickinson and Company

-3.00 (-1.43%)

USD 61.57B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-2.00 (-1.64%)

USD 42.88B
HYB:F HOYA Corporation

-1.65 (-1.33%)

USD 42.41B
RME:F ResMed Inc

-14.90 (-6.56%)

USD 33.80B
RMEA:F Resmed Inc DRC

-0.60 (-2.68%)

USD 33.02B
CBH:F COLOPLAST SP.ADR 1/10 DK1

-0.20 (-1.61%)

USD 27.61B
QS50:F STRAUM.HLD.UNSP.ADR/1/10

N/A

USD 20.01B

ETFs Containing CBHD:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.52% 79% B- 80% B-
Dividend Return 4.80% 71% C- 55% F
Total Return 26.32% 70% C- 75% C
Trailing 12 Months  
Capital Gain 25.31% 79% B- 77% C+
Dividend Return 20.80% 73% C 74% C
Total Return 46.11% 77% C+ 79% B-
Trailing 5 Years  
Capital Gain 17.35% 57% F 55% F
Dividend Return 38.55% 80% B- 67% D+
Total Return 55.89% 68% D+ 61% D-
Average Annual (5 Year Horizon)  
Capital Gain -2.49% 46% F 38% F
Dividend Return 4.49% 53% F 51% F
Total Return 6.98% 76% C+ 76% C+
Risk Return Profile  
Volatility (Standard Deviation) 18.43% 69% C- 67% D+
Risk Adjusted Return 24.38% 57% F 52% F
Market Capitalization 27.31B 90% A- 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector